KALARIS THERAPEUTICS INC

KLRSNASDAQ

🏆 #3452 by market capEarnings Nov 18US Equity

$3.98▲ $0.05 (+1.27%)

Market closed · at close

1h—

24h▲ 1.3%

7d▼ 3.0%

14d▲ 17.4%

30d▼ 10.6%

1y▲ 58.6%

🏦Market Cap

$95M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $3.96 – $4.06
52-Week Range: $2.14 – $11.88
Volume: $1.82B
Avg Volume: $1.32B
Shares Outstanding: 23.8M
Next Earnings: Sep 26, 2026

Fundamentals Snapshot

Annual Revenue: $26M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-2.21
Dividend Yield: —

Why Investors Own KLRS

✓High-growth profile — revenue up +14.3% YoY with expanding US Equity exposure.
✓Healthy economics — 53% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$26M▲ +11.6% YoY

Gross Margin (TTM)

52.8%▲ +2.8% YoY

Operating Income (TTM)

$5M▲ +11.6% YoY

Free Cash Flow (TTM)

$2M▲ +11.6% YoY

About KALARIS THERAPEUTICS INC

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

🦦